Background: Atazanavir is boosted with the cytochrome P450 (CYP) 3A4 inhibitor ritonavir. When combined with the CYP3A4 substrate daclatasvir, the daclatasvir dosage should be reduced from 60 to 30 mg once daily. Recently, cobicistat was licensed as a CYP3A booster and used with atazanavir.
Introduction
Combined treatment for infection with HIV and hepatitis C virus (HCV) is commonly applied in daily practice, because globally 33% of HIV patients are coinfected with HCV. 1, 2 There are a number of combination regimens of specific antivirals available for both treatments.
Atazanavir is an HIV PI that is mainly metabolized by cytochrome P450 (CYP) 3A4 in the liver. To improve the pharmacokinetics (PK) of atazanavir, the PI ritonavir is added as a 'booster'. Ritonavir is a strong inhibitor of CYP3A4 and therefore breakdown of atazanavir is inhibited. This extends the elimination half-life (t 1/2 ) of atazanavir (8.6 versus 6.5 h 3 ) and allows once-daily dosing. 3 Apart from CYP3A4 inhibition, ritonavir inhibits CYP2D6 and P-glycoprotein (P-gp), and it induces e.g. CYP2C9, CYP1A2 and UDP-glucuronosyltransferase (UGT) 1A1. 4 Recently cobicistat became available as an alternative CYP3A booster and is approved to boost atazanavir, darunavir and elvitegravir. 5, 6 Cobicistat is co-formulated with atazanavir (300 mg/ 150 mg). This combination is equally effective as atazanavir/ ritonavir at 300 mg/100 mg. 7 Cobicistat is a specific inhibitor of CYP3A, CYP2D6 and P-gp, but it lacks the inductive capacity of ritonavir. 8 In addition, cobicistat has a more favourable toxicity profile than ritonavir. For example, cobicistat does not adversely affect the lipid profile.
Daclatasvir is part of a number of HCV regimens that target patients infected with genotypes 1, 3 and 4. Daclatasvir is a substrate of CYP3A4 and P-gp. This opens the door for a drug -drug interaction (DDI) with ritonavir and atazanavir. Atazanavir itself also inhibits drug enzymes and transporters such as CYP3A4, CYP2D6, UGT1A1 and organic anion transporting polypeptides (OATPs). According to the label, the dose of daclatasvir should be reduced from 60 to 30 mg once daily when it is administered concomitantly with atazanavir/ritonavir. 9 However, the impact of atazanavir/cobicistat on daclatasvir PK is unknown. Because these drugs will be used in combination in HIV/HCV-coinfected patients, we sought to examine whether atazanavir/cobicistat has the same impact on daclatasvir PK as atazanavir/ritonavir. Our hypothesis is that 30 mg of daclatasvir is the sufficient dose when it is combined with atazanavir/cobicistat, because its CYP3A-inhibitory capacity is comparable to that of atazanavir/ ritonavir.
Patients and methods
This prospective, open-label, two-period, randomized, cross-over trial included 16 healthy subjects, aged 18 -55 years. Main exclusion criteria were estimated glomerular filtration rate (eGFR) ,60 mL/min, positive HIV, HCV or hepatitis B test, abnormal laboratory tests and the use of medication or drugs [except acetaminophen (paracetamol) at ≤2 g/day].
Subjects were equally randomized into two treatment groups (AB and BA). Treatment A (reference) consisted of 10 days of daclatasvir at 30 mg once daily [Daklinza w , Bristol-Myers Squibb (BMS) Pharma EEIG] and the separate compounds atazanavir at 300 mg (Reyataz w , BMS) and ritonavir at 100 mg once daily (Norvir w , AbbVie Ltd). Treatment B (test) consisted of 10 days of daclatasvir at 30 mg once daily and the fixed-dose combination atazanavir/cobicistat at 300/ 150 mg once daily (Evotaz w , BMS). Between the treatments a wash-out period of 11 days was included ( Figure S1 , available as Supplementary data at JAC Online).
On day 10 of both treatments (steady state) the drugs were taken with a standardized breakfast consisting of a glass of milk and two slices of buttered wheat bread with Dutch 48+ cheese (48+ means 25% of saturated fats) and cervelat (396 kCal). A 24 h PK curve was recorded and blood samples were obtained at t¼0 (predose) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 h after intake of the study medication.
Atazanavir and ritonavir plasma concentrations were determined using a modification of a validated HPLC assay with ultraviolet (UV) detection. 10 Cobicistat was determined using a validated LC-MS/MS method with a lower limit of quantification (LLOQ) of 0.031 mg/L. Daclatasvir was determined with a validated UPLC assay with UV detection (LLOQ 0.03 mg/L).
PK parameters (AUC 0 -t , C max , C last , T max , t 1/2 ) were calculated for all drugs using non-compartmental analysis (WinNonlin 6.4, Phoenix 64). To determine bioequivalence between treatments, geometric mean ratios (GMRs) with 90% CI of AUC 0 -t , C max and C last were calculated comparing the effect of atazanavir/ritonavir with the effect of atazanavir/cobicistat on the PK of daclatasvir. Bioequivalence was demonstrated if the 90% CI of the GMR fell within 80%-125%, which is in accordance with international guidelines. 11, 12 For sample size calculation we used power calculation in SAS w 9.2 (paired t-test for lognormal distribution for showing equivalence). We used the previously observed inter-subject variation of 35% and intrasubject variation of 10% for daclatasvir AUC in healthy subjects. 13 For 80% power a sample size of seven subjects needed to be included in the trial to detect bioequivalence for daclatasvir between treatments. To account for possible drop-outs and to follow the FDA guidelines (minimum of 12 subjects required), two groups of 8 subjects were included.
Secondarily, GMRs with 90% CI of atazanavir were calculated comparing the effects of cobicistat and ritonavir on atazanavir PK parameters.
During every visit, safety was assessed by serum biochemistry and haematology and subjects were asked about the presence of adverse Daclatasvir 30 mg/day is the correct dose with atazanavir/cobicistat JAC events (AEs). Data were collected using Castor EDC (Castor Electronic Data Capture, Ciwit BV, Amsterdam, the Netherlands).
Ethics
The study was conducted in Radboud University Medical Center, Nijmegen, the Netherlands and approved by the local ethics committee. The trial was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. All participants signed informed consent prior to screening evaluations (NCT02565888).
Results
All 16 healthy subjects (8 males, 16 Caucasian) completed the study. Median age (range) and BMI (range) were 48.5 (21 -55) years and 24.5 (19.0-29.2) kg/m 2 , respectively. Table 1 displays daclatasvir PK parameters with atazanavir/ ritonavir versus atazanavir/cobicistat. Bioequivalence was established for daclatasvir between treatment groups, because GMR 90% CIs were all within the 80% -120% range: AUC 0 -t 101% (92% -111%), C max 97% (89% -106%) and C last 101% (89% -115%). For atazanavir, exposure after boosting with cobicistat appeared to be lower than after boosting with ritonavir. The GMR values (B versus A) were: AUC 0 -t 82% (75% -79%); C max 74% (68%-81%); and C last 86% (76%-98%). Figure 1 shows the PK curves of daclatasvir and atazanavir for both treatments. Figure S2 shows the PK curves of cobicistat and ritonavir with reference curves obtained from the literature.
No serious adverse events (SAEs) were reported in this trial. However, a total of 139 AEs occurred and 23% were classified as grade 3/4. AEs were comparable between treatment groups. AEs reported (≥5%) are shown per treatment in Table S1 .
All subjects had at least grade 1 hyperbilirubinaemia (.1.0 mg/dL). Ten subjects developed jaundice, of whom six had jaundice during both treatments. Bilirubin concentrations normalized after cessation of atazanavir.
Discussion
The primary objective of our trial was to compare the influences of atazanavir/ritonavir and atazanavir/cobicistat on daclatasvir plasma concentrations. Our hypothesis was confirmed and daclatasvir plasma concentrations were comparable, because bioequivalence was established. Additionally, the daclatasvir plasma concentrations were in line with previously published data in healthy volunteers. 9 Therefore we argue that 30 mg of daclatasvir is the right dose for HCV treatment when used in combination with atazanavir/cobicistat.
The GMR values with 90% CI of atazanavir/cobicistat versus atazanavir/ritonavir (secondary research question) fell outside the range of 80% -120%. Apparently cobicistat administered at a dose of 150 mg once daily is a weaker booster than steady-state ritonavir, since atazanavir plasma concentrations were lower when given with cobicistat than with ritonavir. Phase III studies have produced comparable efficacy and safety data for both treatments.
14 So, these mildly reduced atazanavir levels appear not to have clinical relevance. This is supported by the fact that atazanavir C last in both study arms was .0.15 mg/L, which is the proposed minimal effective concentration. 15 The conclusion that 150 mg of cobicistat is a somewhat weaker CYP3A booster than 100 mg of ritonavir can also be found in a study that described the PK of darunavir/ritonavir and darunavir/cobicistat. 16 In both treatment groups, the PK parameters of atazanavir were increased compared with the reference values shown in Table 1 . We should note that the subjects in the study of Esté vez et al. 17 did not take atazanavir/ritonavir with food, which may explain this difference, as food intake increases the absorption of atazanavir. 3 The reference values of atazanavir/ cobicistat were obtained from a study where the drugs were taken with a light meal (336 kCal), which was similar in our study. 18 Cobicistat and ritonavir exposures were both in line with the literature (Table 1) . Reference values were obtained from studies in healthy volunteers treated with atazanavir/ritonavir or atazanavir/cobicistat. 17, 18 During the trial, unconjugated hyperbilirubinaemia was seen in all subjects and jaundice was reported by 10 subjects. This was an expected AE, caused by UGT1A1 inhibition by atazanavir. UGT1A1 is responsible for the conjugation of bilirubin, so less enzyme is available for bilirubin conjugation. This results in a decreased Smolders et al.
elimination of bilirubin and thus hyperbilirubinaemia (Gilbert's-like syndrome). After cessation of atazanavir, bilirubin levels normalized in all subjects.
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Conclusions
Atazanavir/cobicistat and atazanavir/ritonavir had a similar influence on the PK of daclatasvir in healthy volunteers and are considered to be bioequivalent. The recommended dose of daclatasvir with atazanavir/ritonavir, 30 mg once daily, also applies for cobicistat-boosted atazanavir. Since no unexpected side effects were reported in the trial, this combination can be used safely.
